Geographic Distribution of HCV Genotypes and Efficacy of Direct-Acting Antivirals in Chronic HCV-Infected Patients in North and Northeast China: A Real-World Multicenter Study

Table 5

Treatment response of different DAA regimens from 2018 to 2021.

Duration	DAA regimens	Response rate (CHC)	Response rate (LC)
2017–2019	OBV/PTV/r/DSV	100% (92/92)	97.22% (35/36)
	SOF + RBV	100% (41/41)	85.19% (23/27)
	EBR/GZR	100% (45/45)	100% (17/17)
	SOF + DCV ± RBV	100% (8/8)	100% (20/20)
	ASV + DCV	100% (2/2)	100% (3/3)
	GLE/PIB	100% (4/4)	100% (1/1)
2020–2021	SOF/vel ± rbv	100% (27/27)	100% (41/41)
	SOF/ldv ± rbv	100% (19/19)	100% (20/20)

DAA, directing antiviral agents; CHC, chronic hepatitis C; LC, liver cirrhosis; OBV/PTV/r, ombitasvir/paritaprevir/ritonavir; DSV, dasabuvir; SOF, sofosbuvir; RBV, ribavirin; EBR/GZR, elbasvir/grazoprevir; DCV, daclatasvir; ASV, asunaprevir; GLE/PIB: glecaprevir/pibrentasvir; VEL, velpatasvir; LDV, ledipasvir.